Thermo Fisher Scientific Q4 Adjusted EPS $5.67 Beats $5.64 Estimate, Sales $10.89B Beat $10.73B Estimate
Portfolio Pulse from Benzinga Newsdesk
Thermo Fisher Scientific (NYSE:TMO) exceeded analyst expectations for Q4 with an adjusted EPS of $5.67, surpassing the estimate of $5.64, and reported sales of $10.89B, beating the $10.73B estimate. However, sales saw a 4.93% decrease from the same period last year.
January 31, 2024 | 11:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Thermo Fisher Scientific reported higher-than-expected Q4 earnings and sales, with EPS at $5.67 and sales at $10.89B, indicating a strong financial performance despite a slight decrease in year-over-year sales.
Thermo Fisher's beat on both earnings and sales estimates is likely to be viewed positively by investors, leading to a potential short-term increase in stock price. The decrease in year-over-year sales might temper some of the positive sentiment, but the earnings beat is typically a stronger driver of stock performance in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100